A Primer on the Economics of Prescription Pharmaceutical Pricing in Health Insurance Markets

Forum for Health Economics and Policy

Volumn 14, Issue 1, 2011, Pages

  Berndt, Ernst R ^a   McGuire, Thomas ^b   Newhouse, Joseph P ^c  

^a NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD UNIVERSITY   (United States)

Author keywords

Bertrand competition; brands; generics; health insurance; pharmaceuticals; prices

Indexed keywords

EID: 84885794321     PISSN: None     EISSN: 15589544     Source Type: Journal    
DOI: 10.2202/1558-9544.1301     Document Type: Article

References (47)

1. Abelson, Reed and Natasha Singer (2011), "Pharmacists Fight the Rise of Mail Order", New York Times, March 3. Available online at http://www.nytimes.com/2011/03/04/business/04drug.html?emc=etal&pag ewanted= print, accessed March 4, 2011.
2. Adams, Scott (1997), The Dilbert Future, New York: HarperCollins.
3. Barrueta, Anthony (2003), "Pharmacy Benefit Management Companies (PBMs)", comments of Senior Counsel, Kaiser Foundation Health Plan, Inc., Oakland, California, before the Federal Trade Commission/Department Of Justice Joint Hearings, Health Care and Competition Law and Policy, June 26, 2003, p. 1; accessed online at www.ftc.gov/ogc/healthcarehearings/docs/030626barrueta.pdf.
4. Berndt, Ernst R. (2002), "Pharmaceuticals in U.S. Health Care: Determinants of Quantity and Price", Journal of Economic Perspectives 16(4):45-66, Fall.
5. Berndt, Ernst R. and Murray L. Aitken (2011), "Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century After the 1984 Waxman-Hatch Legislation," International Journal of the Economics of Business, 18(2):177-201, July.
6. Berndt, Ernst R. and Richard G. Frank (2007), "Medicare Part D and Prescription Drug Prices", Survey of Current Business 87(6):59-71, June.
7. Berndt, Ernst R., Richard Mortimer, Ashoke Bhattacharjya, Andrew Parece and Edward Tuttle (2007), "Authorized Generic Drugs, Price Competition and Consumers' Welfare", Health Affairs 26(3):790-9, May/June.
8. Berndt, Ernst R. and Joseph P. Newhouse (2010, 2011), Pricing and Reimbursement in U.S. Pharmaceutical Markets", Cambridge MA: National Bureau of Economic Research, Working Paper No. 16297, August. Revised version forthcoming in Patricia M. Danzon and Sean N. Nicholson, eds., The Economics of the Biopharmaceutical Industry, Oxford: Oxford University Press, 2011.
9. Cook, Anna (1998), How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry, Washington DC: The Congress of the United States, Congressional Budget Office. Available online at http://www.cbo.gov/.
10. Drug Channels (2007a), "Wal-Mart adds some $4 generics (yawn)", September 27. Available at http://www.drugchanels.net/2007/09/wal-mart-addssome4-generics-yawn.html.
11. Drug Channels (2007b), "Wal-Mart's Gain is not Walgreen's Pain", October 2. Available at http://www.drugchannels.net/2007/10/wal-marts-gain-is-notwalgrens-pain.html.
12. Drug Channels (2008a), "Wal-Mart Redux", May 7. Available at http://www.drugchannels.net/2008/05/wal-mart-redux.html.
13. Drug Channels (2008b), "Walgreens' $4.33 Surrender to Wal-Mart", June 25. Available at http://www.drugchannels.net/2008/06/walgreens-433-surrender-to-wal-mart.html.
14. Drug Channels (2008c), "WMT + CAT: Pharmacy's Future?", September 25. Available at http://www.drugchannels.net/2008/09/wmt-cat-pharmacysfuture. html.
15. Drug Channels (2008d), "New Details on WMT-CAT Pharmacy Deal", November 6. Available at http://www.drugchannels.net/2008/11/newdetails-on-wmt-cat-pharmacy-deal.html.
16. Duggan, Mark, Patrick Healy and Fiona Scott Morton (2008), "Providing Prescription Drug Coverage to the Elderly: America's Experiment with Medicare Part D", Journal of Economic Perspectives 22(4):69-92, Fall.
17. Duggan, Mark and Fiona Scott Morton (2010), "The Effect of Medicare Part D on Pharmaceutical Prices and Utilization", American Economic Review 100(1):590-607, March.
18. Ellis, Randall P. and Willard G. Manning (2007), "Optimal Health Insurance for Prevention and Treatment," Journal of Health Economics 26(6):1128-50.
19. Federal Trade Commission [2009], Emerging Health Care Issues: Follow-on Biologic Drug Competition, June. Available online at www.ftc.gov/opa/2009/06/biologics.shtru.
20. Federal Trade Commission (2009a), Authorized Generics: An Interim Report of the Federal Trade Commission, June. Available at http://www.ftc.gov/opa/2009/06/generics.shtm, last accessed 14 July 2010.
21. Federal Trade Commission (2009b), Emerging Health Care Issues: Follow-on Biologic Drug Competition, June. Available online at www.ftc.gov/opa/2009/06/biologics.shtm.
22. Federal Trade Commission (2011), Authorized Generic Drugs: Short-Term Effects and Long-Term Impact, August. Available online at www.ftc.gov/opa/2011/08/genericdrugs.shtm.
23. Frank, Richard G. (2001), "Prescription Drug Prices: Why Some Pay More Than Others Do", Health Affairs 20(2):115-28, March/April.
24. Frank, Richard G. and Joseph P. Newhouse (2007), "Mending the Medicare Prescription Drug Benefit: Improving Consumer Choices and Restructuring Purchasing", Washington DC: The Brookings Institution, Hamilton Project Discussion Paper 2007-03, April.
25. Frank, Richard G. and Joseph P. Newhouse (2008), "Should Drug Prices Be Negotiated Under Part D of Medicare? And If So, How?", Health Affairs 27(1):33-43, January/February.
26. Frank, Richard G. and David S. Salkever (1992), "Pricing, Patent Loss and the Market for Pharmaceuticals", Southern Economic Journal 59(2):165-179, October.
27. Frank, Richard G. and David S. Salkever (1997), "Generic Entry and the Pricing of Pharmaceuticals", Journal of Economics and Management Strategy 6(1):75-90, Spring.
28. Frueh, Felix W., Shashi Amur, Padmaja Mummaneni, Robert S. Epstein, Ronald E. Aubert, Teresa M. DeLuca, Robert R. Verbrugge, Gilbert J. Burckart and Lawrence J. Lesko (2008), "Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use", Pharmacotherapy 28(8):992-998, August.
29. Gaynor, Martin, Deborah Haas-Wilson, and William B. Vogt (2000), "Are Invisible Hands Good Hands? Moral Hazard, Competition, and the Second-Best in Health Care Markets", Journal of Political Economy 108(5):992-1005, October.
30. Glazer, Jacob, Haiden A. Huskamp and Thomas G. McGuire (2011), "A Prescription for Drug Formulary Evaluation", Boston, MA: Harvard Medical School, Department of Health Care Policy, unpublished, February 25.
31. Goldman, Dana P., Geoffrey F. Joyce, Grant Lawless, William H. Crown and Vincent Willey (2006), "Benefit Design and Specialty Drug Use", Health Affairs 25(5):1319-31, September/October.
32. Grabowski, Henry G. (2008), "Follow-on Biologics: Data Exclusivity and the Balance Between Innovation and Competition", Nature Reviews: Drug Discovery 7:479-88, June, doi:10.1038/nrd2532.
33. Grabowski, Henry G., Iain M. Cockburn and Genia Long (2006), "The Market for Follow-On Biologics: How Will It Evolve?", Health Affairs 25(5):1.
34. Grabowski, Henry G. and John M. Vernon [1992], "Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act", Journal of Law and Economics 35:331-340, October.
35. Grabowski, Henry G. and John M. Vernon (1996), "Longer Patents for Increased Generic Competition in the US: The Waxman-Hatch Act after One Decade," Pharmacoeconomics 10 Suppl2:110-123.
36. Kanavos, Panos and Uwe Reinhardt (2003), "Reference Pricing in the United States?," Health Affairs 22(3):16-30, May/June.
37. Lakdawalla, Darius and Neeraj Sood (2009) "Innovation and the Welfare Effects of Public Drug Insurance," Journal of Public Economics 93:541-48.
38. Mas-Colell, Andreu, Michael D. Whinston, and Jerry R. Green (1995), Microeconomic Theory, New York: Oxford University Press.
39. Medco (2011), 2010 Drug Trend Report. Available online at www.medco.com; also available at www.drugtrend.com.
40. Pauly, Mark V. (2010), "Insurance and Drug Spending", Philadelphia, PA: University of Pennsylvania, The Wharton School, unpublished manuscript, December 10. Forthcoming in Patricia M. Danzon and Sean N. Nicholson, eds., The Economics of the Biopharmaceutical Industry, Oxford, UK: Oxford University Press, 2011.
41. Pindyck, Robert S. and Daniel L. Rubinfeld (2009), Microeconomics, 7th Edition, Upper Saddle River, New Jersey: Pearson Prentice-Hall.
42. Pollack, Andrew (2011), "Coupons for Patients, but Higher Bills for Insurers", New York Times, January 2. Available online at http://www.nytimes.com/2011/01/02/business/02coupon.html?_r=1&page wanted=print, last accessed 10 March 2011.
43. Reiffen, David E. and Michael E. Ward (2005), "Generic Drug Industry Dynamics", Review of Economics and Statistics 87(1):37-49.
44. Reiffen, David E. and Michael E. Ward (2007), "'Branded Generics' As A Strategy to Limit Cannibalization of Pharmaceutical Markets", Managerial and Decision Economics 28:251-65.
45. Saha, Atanu, Henry G. Grabowski, Howard M. Birnbaum, Paul E. Greenberg and Oded Bizan (2006), "Generic Competition in the U.S. Pharmaceutical Industry", International Journal of the Economics of Business 13(1):15-38, February.
46. Trusheim, Mark R., Murray L. Aitken and Ernst R. Berndt (2010), "Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ From Small Molecules?", Forum for Health Economics & Policy, Manuscript 1200, June, 48pp. Available online at.
47. WalMart (2010), "$4 Prescriptions Program", available online at http://www.walmart.com/p/4-Prescriptions-Program/546834, last accessed March 21, 2010.